US Senator Bernie Sanders says the FDA should allow pharmacies and generic manufacturers to make low-cost copies of Catalyst Pharma’s rare disease drug Firdapse, which is at the heart of a
The controversy over rising drug prices in the US has been reignited after it emerged that the yearly cost of the life-sustaining rare disease drug Firdapse has been hiked from free to more
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh